TRVN Research and Charts

TRVN - Trevena Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-16 (Delayed quote data 2025-01-06)

Last 1.81	Change ⇑ +0.10 (+5.85%)	Volume 7,525
	Open 1.59	High 1.91	Low 1.59

8EMA (Daily) 1.68	40EMA (Daily) 1.83	50EMA (Daily) 1.97	STO (Daily) 30.213	MACD Hist (Daily) 0.056
8EMA (Weekly) 1.807	40EMA (Weekly) 6.11	50EMA (Weekly) 9.53	STO (Weekly) 18.518	MACD Hist (Weekly) 0.733


Company Profile
Trevena Inc is an American biotechnology company. The portfolio pipeline is focused on medicines targeting pain management: TRV734: oral medicine for moderate to severe pain; TRV250: oral medicine for migraines; and TRV027: treatment for acute heart failure. Its leading product is oliceridine (TRV130), a protein-based chemical meant to manage moderate to severe acute pain.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.